Article Text

Download PDFPDF
Safety update: dupilumab and ocular adverse reactions


Overview of: Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management. Drug Safety Update 2022;16(4): 1.

  • Health Care Quality, Access, and Evaluation
  • Drug-Related Side Effects and Adverse Reactions

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.